Skin conditions affect millions of Americans, but patients who seek treatment for their skin condition often face the difficulty of finding an available specialist in their area, according to a new paper published by Derma Care Access Network.
A paper recently published by Derma Care Access Network, an advocacy group that supports informed policies on access for dermatological care, discussed a variety of skin conditions that commonly affect Americans and how to overcome the challenges of accessing the necessary care.
Skin conditions affect millions of Americans and often times come with painful symptoms. The specific skin conditions that the paper discusses include:
The authors of the paper emphasized the deeper problems that these skin conditions can cause. For example, those with psoriasis are at a greater risk of associated comorbidities such as diabetes, chronic pulmonary disease, and others. People with these common skin conditions also face high costs for accessing healthcare providers and drugs for treatment. According to the paper, the direct cost of skin disease is nearly $75 billion a year and 61% of that total is attributed to medical costs.
Patients who seek treatment for their skin conditions often face the difficulty of finding an available specialist in their area, as many only practice in densely populated areas, the authors explained. Additionally, some health plans do not cover dermatologists’ visits including many practices that lack the resources to process patients who have Medicare or Medicaid.
“Patients with moderate-to-severe conditions, however, typically do need to see a specialist," the report noted. "Yet a shortage of dermatologists, reportedly driven by a shortage in available training spots for medical students hoping to enter the field, makes finding an available dermatology care provider challenging. Although only 20% of dermatologists focus on cosmetic treatments and procedures rather than treating traditional skin conditions, wait times to see a dermatologist can be painfully long.”
The access challenges are continued once a patient meets with a dermatologist, as many of the sophisticated biologic medicines have high costs and many health plans require prior authorization for these biologic treatments. The prior authorization may include step therapy, which would require patients to fail a lower-cost treatment that the insurers prefer before getting approved for the innovative treatment.
In response to the difficulty of treatment access for skin conditions, new state bills have been introduced. Legislation in certain states have imposed limitations on when health plans can require step therapy. The paper suggested that additional federal and state legislation is needed in order to prioritize patient treatment.
“Proper dermatological care stands to improve patients’ health, productivity and quality of life. But those improvements are predicated on access to the specialists who can guide their treatment and the innovative medicines that can change their lives,” the authors concluded.
FDA Approves Expanded Indication of Eculizumab for Pediatric Generalized Myasthenia Gravis
March 15th 2025The FDA first approved eculizumab for use in adult patients with generalized myasthenia gravis in 2017, before expanding the indication to include pediatric patients who are 6 years or older and positive for antiacetylcholine receptor antibodies.
Read More
Regenerating Neurons, Muscle, and Hope in the Field of Muscular Dystrophy
March 13th 2025The 2025 Muscular Dystrophy Association Clinical & Scientific Conference, convening in Dallas, Texas, from March 16-18, will feature clinical updates, expert insights, and breaking trial findings that sum up to a new frontier of care for neuromuscular diseases.
Read More
Addressing Financial Aid and Patient Independence as Part of Atopic Dermatitis Care
March 13th 2025Discussions centered on mitigating the financial burden of pediatric atopic dermatitis through financial aid programs and enhancing support for young patients to independently manage their condition were emphasized at this year’s 2025 American Academy of Dermatology meeting.
Read More